Institution
Saga Group
About: Saga Group is a based out in . It is known for research contribution in the topics: Population & Cancer. The organization has 5144 authors who have published 6947 publications receiving 151385 citations.
Topics: Population, Cancer, Cell culture, Periostin, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is reported that a novel molecule, MD-2, is requisite for LPS signaling of TLR4, which is physically associated withTLR4 on the cell surface and confers responsiveness to LPS.
Abstract: Toll-like receptor 4 (TLR4) is a mammalian homologue of Drosophila Toll, a leucine-rich repeat molecule that can trigger innate responses against pathogens. The TLR4 gene has recently been shown to be mutated in C3H/HeJ and C57BL/10ScCr mice, both of which are low responders to lipopolysaccharide (LPS). TLR4 may be a long-sought receptor for LPS. However, transfection of TLR4 does not confer LPS responsiveness on a recipient cell line, suggesting a requirement for an additional molecule. Here, we report that a novel molecule, MD-2, is requisite for LPS signaling of TLR4. MD-2 is physically associated with TLR4 on the cell surface and confers responsiveness to LPS. MD-2 is thus a link between TLR4 and LPS signaling. Identification of this new receptor complex has potential implications for understanding host defense, as well as pathophysiologic, mechanisms.
2,123 citations
••
TL;DR: S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer, and progression-free survival was significantly longer in patients assigned to S-1plus cis Platin than in those assigned to s-1 alone.
Abstract: Summary Background Phase I/II clinical trials of S-1 plus cisplatin for advanced gastric cancer have yielded good responses and the treatment was well tolerated. In this S-1 Plus cisplatin versus S-1 In RCT In the Treatment for Stomach cancer (SPIRITS) trial, we aimed to verify that overall survival was better in patients with advanced gastric cancer treated with S-1 plus cisplatin than with S-1 alone. Methods In this phase III trial, chemotherapy-naive patients with advanced gastric cancer were enrolled betweeen March 26, 2002, and Nov 30, 2004, at 38 centres in Japan, and randomly assigned to S-1 plus cisplatin or S-1 alone. In patients assigned to S-1 plus cisplatin, S-1 (40–60 mg depending on patient's body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m 2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle. Those assigned to S-1 alone received the same dose of S-1 twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportions of responders, and safety. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00150670. Findings 305 patients were enrolled; seven patients were ineligible or withdrew consent, therefore, 148 patients were assigned to S-1 plus cisplatin and 150 patients were assigned to S-1 alone. Median overall survival was significantly longer in patients assigned to S-1 plus cisplatin (13·0 months [IQR 7·6–21·9]) than in those assigned to S-1 alone (11·0 months [5·6–19·8]; hazard ratio for death, 0·77; 95% CI 0·61–0·98; p=0·04). Progression-free survival was significantly longer in patients assigned to S-1 plus cisplatin than in those assigned to S-1 alone (median progression-free survival 6·0 months [3·3–12·9] vs 4·0 months [2·1–6·8]; p Interpretation S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer.
1,641 citations
•
TL;DR: Classification criteria for adult Still's disease was attempted by analyzing the data obtained through a multicenter survey of 90 Japanese patients with this disease and of 267 control patients and the proposed criteria consisted of fever, arthralgia, typical rash, and leukocytosis as major criteria.
Abstract: We have attempted to design classification criteria for adult Still's disease by analyzing the data obtained through a multicenter survey of 90 Japanese patients with this disease and of 267 control patients. The proposed criteria consisted of fever, arthralgia, typical rash, and leukocytosis as major, and sore throat, lymphadenopathy and/or splenomegaly, liver dysfunction, and the absence of rheumatoid factor and antinuclear antibody as minor criteria. Requiring 5 or more criteria including 2 or more major criteria yielded 96.2% sensitivity and 92.1% specificity. However, an exclusion process will be needed for an accurate classification, since this disease is relatively rare.
1,499 citations
••
TL;DR: A national single-step genetic evaluation with the pedigree relationship matrix augmented with genomic information provided genomic predictions with accuracy and bias comparable to multiple-step procedures and could account for any population or data structure.
1,095 citations
••
TL;DR: It is found that in MD-2−/− embryonic fibroblasts, TLR4 was not able to reach the plasma membrane and predominantly resided in the Golgi apparatus, whereas TLR3 was distributed at the leading edge surface of cells in wild-type embryonic fibrablasts andMD-2 is essential for correct intracellular distribution and LPS-recognition ofTLR4.
Abstract: Toll-like receptor 4 (TLR4) mediates lipopolysaccharide (LPS) signaling in a variety of cell types. MD-2 is associated with the extracellular domain of TLR4 and augments TLR4-dependent LPS responses in vitro. We show here that MD-2(-/-) mice do not respond to LPS, do survive endotoxic shock but are susceptible to Salmonella typhimurium infection. We found that in MD-2(-/-) embryonic fibroblasts, TLR4 was not able to reach the plasma membrane and predominantly resided in the Golgi apparatus, whereas TLR4 was distributed at the leading edge surface of cells in wild-type embryonic fibroblasts. Thus, MD-2 is essential for correct intracellular distribution and LPS-recognition of TLR4.
1,035 citations
Authors
Showing all 5144 results
Name | H-index | Papers | Citations |
---|---|---|---|
Shigekazu Nagata | 124 | 428 | 85675 |
Raif S. Geha | 112 | 638 | 43559 |
Ikuo Ueda | 106 | 1053 | 48642 |
Nosratola D. Vaziri | 98 | 708 | 34586 |
Yasufumi Kaneda | 92 | 632 | 37989 |
Raymond Sawaya | 90 | 340 | 28550 |
Hiroshi Shibasaki | 86 | 598 | 27161 |
Kensuke Miyake | 84 | 259 | 28066 |
Michio Sata | 73 | 751 | 24254 |
Akira Nakagawara | 68 | 328 | 16460 |
Ryusuke Kakigi | 64 | 493 | 15943 |
Yuichiro Tanaka | 62 | 356 | 11324 |
Akira Kudo | 61 | 197 | 13558 |
Akio Ikeda | 59 | 402 | 11819 |
Kenji Izuhara | 57 | 307 | 11135 |